Select your country

New Russian Consul General visits STADA as first German company

  • 18/08/2015
  • Press Release

Bad Vilbel, August 18, 2015 –

Today, only a few weeks after taking office, Alexander Bulay, the newly-appointed Consul General of the Russian Federation in Frankfurt am Main, visited STADA Arzneimittel AG as the first German company. Bulay and STADA's Chairman of the Executive Board, Hartmut Retzlaff, discussed the economic relationship between Germany and Russia, among other things. Their major topic in this context was the Group’s engagement in Russia, where STADA plays an important role as it is the number two regional producer in the Russian pharmaceutical market.

"It's an honor to welcome Mister Bulay so shortly after his taking office. Russia is, after all, a very important market for us to which we remain committed despite the political differences and the present difficult economic situation", says Retzlaff, pleased about the meeting with the new Consul General. During their conversation, both sides were confident that the tensions faced by the economic relationship between Germany and Russia will be eased in the foreseeable future.

"I really wanted to establish personal contact with STADA as soon as possible. Not only does the company play a vital role in the Russian pharmaceutical market, it is also a very reliable partner in the region", says Bulay about the reasons behind his visit to Bad Vilbel. The Consul General was accompanied, among others, by Sergej Rodionov from the Association of the Russian Economy in Germany.

STADA has been active in the Russian market for about ten years now. In financial year 2014, the Group achieved sales in Russia in the amount of Euro 360.7 million and employed 2,343 people in the country.

STADA Arzneimittel AG is a publicly-listed company with headquarters in Bad Vilbel, Germany. STADA consistently focuses on a multi-pillar strategy of generics and branded products (OTC) with an increasingly international market orientation. The Group is the only independent generics producer in Germany. STADA is represented in more than 30 countries with approximately 50 sales companies worldwide. Branded products such as Grippostad and Ladival are among the highest selling in their product category in Germany. In financial year 2014, STADA achieved Group sales of Euro 2,062.2 million, adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of Euro 431.9 million and adjusted net income of Euro 186.2 million. As of December 31, 2014, STADA employed 10,363 people worldwide.

About STADA Arzneimittel AG

For additional information, please contact:

 

STADA Arzneimittel AG
Media Relations
61118 Bad Vilbel – Germany
Tel.: +49(0) 6101 603-165
Fax: +49(0) 6101 603-215
E-Mail: press@stada.de